An interventional study of Recorded Parent/Caregiver Voice Playback in Neonatal Opioid Withdrawal Syndrome, Prenatal Opioid Exposure and Opioid Withdrawal, sponsored by University of Manitoba. Not yet recruiting at 2 sites in Canada. Open to participants aged 0 Days to 28 Days. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by University of Manitoba · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Neonatal opioid withdrawal syndrome (NOWS) can affect a newborn infant's ability to eat, sleep, and be consoled after exposure to opioids before birth. Standard care at the participating neonatal units uses the Eat, Sleep, Console (ESC) approach, which emphasizes supportive care and involvement of parents and caregivers.
VOICE-NAS is a two-centre feasibility study evaluating whether a recorded parent/caregiver voice can be safely and practically added to usual ESC-based care for infants with NOWS. Approximately 15 to 20 infants will be enrolled at HSC Women's Hospital and St. Boniface Hospital in Winnipeg, Manitoba.
A parent or caregiver will make a short voice recording in their preferred or native language. The recording may include natural talking, reading, singing, storytelling, or comforting words. The recording will be played for the infant during clinically appropriate feeding and settling periods, usually during the latter part of a feed and/or after feeding while the infant is trying to settle or sleep. Playback will generally last about 20 minutes and will be delivered at a controlled sound level.
The main purpose of the study is to determine whether the intervention can be delivered consistently and safely within routine NICU care. The study will measure whether usable voice recordings can be obtained, how often planned playback sessions are successfully delivered, reasons sessions are missed or stopped, caregiver acceptability, staff workflow issues, and any signs of intolerance.
Clinical information such as ESC assessments, feeding support, medication treatment for NOWS, and hospital length of stay will also be described. The study is not designed to determine whether recorded voice therapy is effective. Results will be used to help design a future larger clinical trial.
VOICE-NAS is a prospective, two-site, single-arm feasibility study evaluating recorded parent/caregiver voice playback as a non-pharmacologic adjunct to standard Eat, Sleep, Console (ESC)-based care for infants with neonatal opioid withdrawal syndrome (NOWS).
Approximately 15-20 infants will be enrolled from the neonatal intensive care units at HSC Women's Hospital and St. Boniface Hospital in Winnipeg, Manitoba. Eligible infants will have prenatal opioid exposure and clinical NOWS requiring ongoing NICU management under an ESC-based approach. Opioid-associated polysubstance exposure will not exclude participation if the infant otherwise meets eligibility criteria.
Following written informed consent from the parent/legal guardian, a participating parent/caregiver will provide a recorded voice sample. Caregivers will be encouraged to speak naturally in their preferred or native language; English or French is not required. Recording content may include natural speech, reading, singing, storytelling, or comforting words. The research team is not required to translate the recording content.
Recorded voice playback will be integrated into clinically appropriate feeding and settling periods. Playback may begin during the latter part of feeding and/or immediately after feeding while the infant is settling or attempting to sleep. Direct live parent/caregiver interaction, including feeding, holding, skin-to-skin contact, talking, and consoling, will always take priority over recorded playback.
The initial standardized audio-delivery pathway will use the Dräger Babyleo TN500 developmental-care audio pathway when clinically and operationally available. Playback will be targeted at approximately 45-50 dB(A) at the infant position and will not exceed the protocol-defined maximum of 55 dB(A). Planned playback sessions will generally last approximately 20 minutes unless stopped earlier.
Playback will be withheld, paused, or discontinued if the infant develops signs of distress or clinical instability; if a clinical procedure, assessment, feeding need, or other care activity takes priority; if environmental conditions are unsuitable; if the parent/caregiver requests that playback stop; if the treating clinical team considers continued playback inappropriate; or if the protocol-defined sound parameters cannot be maintained.
The study does not alter or delay standard NOWS management. Decisions regarding ESC care, feeding support, pharmacologic treatment, monitoring, transfer, or discharge will remain under the responsibility of the treating clinical team.
The primary focus is feasibility. Key feasibility outcomes will include successful acquisition of a usable parent/caregiver voice recording and the proportion of prescribed playback sessions successfully delivered. Additional measures will include recruitment and consent, time to obtain a usable recording, missed or interrupted sessions and their reasons, protocol deviations, device or workflow issues, caregiver acceptability, staff implementation burden, tolerability, and completeness of study data.
Exploratory clinical variables will include routine ESC assessments, feeding support including nasogastric feeding where required, pharmacologic treatment for NOWS, cumulative medication exposure where available, treatment duration, medical readiness for discharge, and hospital length of stay.
Because this is a small feasibility study without a control group, analyses will be primarily descriptive and estimation-based. The study is not powered for efficacy testing, and no formal between-group hypothesis testing or multivariable modeling is planned. Findings will be used to refine the intervention and procedures and to inform the design of a future randomized efficacy trial.
68 studies on the registry are indexed under Neonatal Abstinence Syndrome; 6 are open to participants now.
This study's planned enrollment of 20 is below the median of 48 across 52 interventional studies indexed under Neonatal Abstinence Syndrome.
Browse Neonatal Abstinence Syndrome studies →University of Manitoba is the lead sponsor of 555 studies on the registry; 88 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Requirement for nasal continuous positive airway pressure (NCPAP/CPAP) or other respiratory support for an independent respiratory condition at the time the intervention would be delivered.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All enrolled infants will receive standard Eat, Sleep, Console (ESC)-based care together with the recorded parent/caregiver voice intervention. A parent/caregiver will provide a voice recording in their preferred or native language. Playback will be integrated into clinically appropriate feeding and settling periods, generally during the latter part of feeding and/or immediately after feeding while the infant is settling or attempting to sleep. Direct parent/caregiver interaction and all clinically indicated care will take priority over recorded playback.
Behavioral: Recorded Parent/Caregiver Voice Playback
A participating parent/caregiver will provide a recorded voice sample using natural speech in their preferred or native language. The recording may include talking, reading, singing, storytelling, or comforting words. The recording will be played to the infant during protocol-defined, clinically appropriate feeding and settling periods, generally during the latter part of feeding and/or immediately after feeding while the infant is attempting to settle or sleep. Playback sessions will generally last approximately 20 minutes unless stopped earlier. Sound will be targeted at approximately 45-50 dB(A) at the infant position and will not exceed the protocol-defined maximum of 55 dB(A). Playback will be withheld, paused, or discontinued for infant distress or clinical instability, clinical procedures or care needs, direct parent/caregiver interaction, unsuitable environmental conditions, parent/caregiver request, treating-team concern, or inability to maintain protocol-defined sound paramet
Proportion of Enrolled Infants With a Usable Parent/Caregiver Voice Recording Obtained
Number of enrolled infants for whom a usable parent/caregiver voice recording is successfully obtained, divided by the total number of enrolled infants, expressed as a percentage. A usable recording is one that can be used for protocol-defined playback.
Time frame: From enrollment until the first usable parent/caregiver voice recording is obtained, assessed up to 1 day after enrollment
Proportion of Prescribed Voice Playback Sessions Successfully Delivered
Number of protocol-prescribed recorded parent/caregiver voice playback sessions successfully delivered, divided by the total number of prescribed playback sessions, expressed as a percentage. Sessions that are missed, withheld, interrupted, or discontinued will be documented together with the reason.
Time frame: From the first planned playback session through completion of the intervention period, assessed up to 28 days after enrollment
Proportion of Eligible Infants Enrolled
Number of eligible infants whose parent/legal guardian provides consent and who are enrolled, divided by the total number of eligible infants approached for participation, expressed as a percentage.
Time frame: Throughout the recruitment period, approximately 12 months
Time From Enrollment to Availability of a Usable Parent/Caregiver Voice Recording
Elapsed time between study enrollment and availability of the first usable parent/caregiver voice recording for intervention delivery.
Time frame: From enrollment until the first usable parent/caregiver voice recording is available, assessed up to 1 day after enrollment
Occurrence of Infant Intolerance During Recorded Voice Playback
Number and proportion of infants with a documented behavioral or physiological concern temporally associated with playback that results in pausing, withholding, or discontinuing a session.
Time frame: From the first playback session through completion of the intervention period, assessed up to 28 days after enrollment
Parent/Caregiver Acceptability of the Recorded Voice Intervention
Acceptability of the intervention as assessed using the study-specific parent/caregiver acceptability questionnaire, including perceived ease of providing the recording and acceptability of using recorded voice as part of the infant's supportive care. Results will be summarized descriptively.
Time frame: At completion of the intervention period or before hospital discharge, whichever occurs first, assessed up to 28 days after enrollment
Frequency of Protocol Deviations and Intervention Delivery Problems
Number and type of protocol deviations, equipment or sound-delivery issues, workflow barriers, and other implementation problems occurring during study participation.
Time frame: From initiation through completion of the intervention period, assessed up to 28 days after enrollment
Pharmacologic Treatment for NOWS
Occurrence and amount of pharmacologic treatment for neonatal opioid withdrawal syndrome, including PRN and scheduled/maintenance opioid therapy and adjunct medications where applicable.
Time frame: From enrollment through hospital discharge, assessed over an anticipated period of up to 28 days
Hospital Length of Stay
Number of days from hospital admission to hospital discharge.
Time frame: From hospital admission until hospital discharge, assessed over an anticipated period of up to 28 days
Plan to share: No
Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.
Of 18 interventional studies with no phase under Neonatal Abstinence Syndrome, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neonatal Abstinence Syndrome →